Guilu-Erxian-Glue alleviates Tripterygium wilfordii polyglycoside-induced oligoasthenospermia in rats by resisting ferroptosis via the Keap1/Nrf2/GPX4 signaling pathway

Context Guilu-Erxian-Glue (GLEXG) is a traditional Chinese formula used to improve male reproductive dysfunction. Objective To investigate the ferroptosis resistance of GLEXG in the improvement of semen quality in the oligoasthenospermia (OAS) rat model. Materials and methods Male Sprague-Dawley (SD) rats were administered Tripterygium wilfordii polyglycoside, a compound extracted from Tripterygium wilfordii Hook F. (Celastraceae), at a dose of 40 mg/kg/day, to establish an OAS model. Fifty-four SD rats were randomly divided into six groups: sham, model, low-dose GLEXG (GLEXGL, 0.25 g/kg/day), moderate-dose GLEXG (GLEXGM, 0.50 g/kg/day), high-dose GLEXG (GLEXGH, 1.00 g/kg/day) and vitamin E (0.01 g/kg/day) group. The semen quality, structure and function of sperm mitochondria, histopathology, levels of oxidative stress and iron, and mRNA levels and protein expression in the Keap1/Nrf2/GPX4 pathway, were analyzed. Results Compared with the model group, GLEXGH significantly improved sperm concentration (35.73 +/- 15.42 vs. 17.40 +/- 4.12, p < 0.05) and motility (58.59 +/- 11.06 vs. 28.59 +/- 9.42, p < 0.001), and mitigated testicular histopathology. Moreover, GLEXGH markedly reduced the ROS level (5684.28 +/- 1345.47 vs. 15500.44 +/- 2307.39, p < 0.001) and increased the GPX4 level (48.53 +/- 10.78 vs. 23.14 +/- 11.04, p < 0.01), decreased the ferrous iron level (36.31 +/- 3.66 vs. 48.64 +/- 7.74, p < 0.05), and rescued sperm mitochondrial morphology and potential via activating the Keap1/Nrf2/GPX4 pathway. Discussion and conclusions Ferroptosis resistance from GLEXG might be driven by activation of the Keap1/Nrf2/GPX4 pathway. Targeting ferroptosis is a novel approach for OAS therapy.

Automated summary

This study investigated the ferroptosis resistance of the traditional Chinese medicine Guilu-Erxian-Glue (GLEXG) in improving semen quality in the oligoasthenospermia (OAS) rat model. The results showed that high-dose GLEXG significantly improved sperm concentration and motility, mitigated testicular histopathology, and activated the Keap1/Nrf2/GPX4 pathway to reduce oxidative stress and iron levels, and restore sperm mitochondrial morphology and potential. Targeting ferroptosis may be a novel approach for OAS therapy.